Opicapone, Levodopa, and AADC Inhibitor Regimen for Parkinson’s
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease do not slow the progression of the disease and are primarily focused on managing symptoms, with no pharmacotherapy showing a relevant delay in disease progression, and there is a challenge in improving ON time without increasing dyskinesia.
Innovation Solution
Administering opicapone, levodopa, and an AADC inhibitor such as carbidopa or benserazide to patients not previously treated with opicapone, either before starting treatment or as adjunctive therapy, to delay the progression of Parkinson's disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional dopaminergic therapies (dopamine agonists, monoamine oxidase inhibitors, levodopa) are used to treat Parkinson's disease, then motor symptoms such as tremor, bradykinesia, and rigidity can be ameliorated, but the progression of the disease is not slowed and motor fluctuations occur over time
Solution Approach 1:
The patent introduces a novel COMT inhibitor (opicapone) with distinct pharmacological parameters compared to existing COMT inhibitors. This new compound modifies the enzymatic inhibition parameters, achieving prolonged and more potent inhibition of catechol-O-methyltransferase, thereby changing the pharmacokinetic profile of levodopa and extending its therapeutic window without the motor fluctuations associated with conventional treatments
Solution Approach 2:
The invention employs a composite therapeutic approach combining levodopa, an AADC inhibitor (carbidopa or benserazide), and the novel COMT inhibitor opicapone. This multi-component formulation creates a synergistic effect where each agent contributes to different aspects of dopamine metabolism control, achieving both symptom management and disease modification that neither agent could achieve alone
2Reliability
If levodopa is used to increase dopamine levels in the brain, then motor symptoms are improved, but dyskinesia and motor fluctuations increase over time
Solution Approach 1:
The patent introduces opicapone as an intermediary substance that modulates the relationship between levodopa and the body's dopamine metabolism systems. By providing potent and prolonged COMT inhibition, opicapone acts as a mediator that stabilizes levodopa levels in the brain, preventing the peaks and troughs that cause dyskinesia while maintaining effective symptom control
Solution Approach 2:
The combination of AADC inhibitor and COMT inhibitor provides preliminary protection against peripheral metabolism of levodopa before it reaches the brain. This pre-emptive action ensures that levodopa is converted to dopamine more efficiently and consistently, reducing the variability in brain dopamine levels that leads to dyskinesia and motor fluctuations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This regimen significantly delays the progression of Parkinson's disease by reducing OFF time and potentially increasing ON time without significantly increasing dyskinesia, with noticeable effects after at least one month and up to one year.
Implementation Method 1
opicapone, a novel, selective, and potent catechol-O-methyltransferase (COMT) inhibitor
Implementation Method 2
an amino acid decarboxylase inhibitor (AADC inhibitor, AADCi)
Implementation Method 3
levodopa (L-DOPA) optionally together with an amino acid decarboxylase inhibitor (AADC inhibitor, AADCi)
Data Source
AI summary
Opicapone, levodopa and an AADC inhibitor are described for use in slowing the progression of Parkinson's Disease.